Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanism to induce central tolerance Lead program in Type 1 diabetes is advancing toward the clinic, with pipeline opportunities in a broad range of autoimmune diseases Company appoints Jason F. Cole, experienced biotech leader and company builder, as Chief Executive Officer Oct. 28, 2025 -- Zag Bio™, Inc., a biotechnology company pioneering thymus-target

SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-signaling cascade in malfunctioning cone photoreceptors Delivered through a single intravitreal injection, SPVN20 targets prevalent retinal diseases with no existing standard of care independently of their causes 28 October 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today announced that the first patient has been s

Oct. 28, 2025 -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra

Oct. 27, 2025 -- MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing in the development of novel bacteriophage therapeutics, announced on October 27 that it received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety (MFDS) on October 21 for MP101, its investigational bacteriophage therapy for patients with acute pneumonia. With this approval, MicrobiotiX becomes the first company in Korea to initiate a first-in-human (FIH) clinical trial for a bacte

Oct. 27, 2025 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation (RPDD) for iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid

Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages Broad mechanism of action of QEL-005 provides clear product differentiation compared to CAR-T and other B-cell depletion approaches, offering a potentially safer and better tolerated therapeutic option Data being presented supports CTA filings in Q4 ahead of initiating the CHILL

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation of dosing in the coming weeks Cohort 4 dose is potentially more reflective of the clinical efficacy threshold given positive trend in observations on multiple immunological biomarkers from the previous six patients in Cohorts 1 through 3, the

Oct. 24, 2025 -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc received a controlling interest in N

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures Oct. 24, 2025 -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presented Data underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet need Novartis to hold virtual investor event following ACR highlighting immunology pipel